Your browser doesn't support javascript.
loading
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Geelen, Inge G P; Gullaksen, Stein-Erik; Ilander, Mette M; Olssen-Strömberg, Ulla; Mustjoki, Satu; Richter, Johan; Blijlevens, Nicole M A; Smit, Willem M; Gjertsen, Bjorn T; Gedde-Dahl, Tobias; Markevärn, Berit; Koppes, Malika M A; Westerweel, Peter E; Hjorth-Hansen, Henrik; Janssen, Jeroen J W M.
  • Geelen IGP; Department of Internal Medicine / Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. i.geelen@erasmusmc.nl.
  • Gullaksen SE; Centre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Ilander MM; Department of Internal Medicine, Hematology section, Helse Bergen, Bergen, Norway.
  • Olssen-Strömberg U; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland.
  • Mustjoki S; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Richter J; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland.
  • Blijlevens NMA; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
  • Smit WM; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
  • Gjertsen BT; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Gedde-Dahl T; Department of Hematology, Radboud UMC, Nijmegen, The Netherlands.
  • Markevärn B; Department of Hematology, Medical Spectrum Twente, Enschede, The Netherlands.
  • Koppes MMA; Centre of Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Westerweel PE; Department of Internal Medicine, Hematology section, Helse Bergen, Bergen, Norway.
  • Hjorth-Hansen H; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Janssen JJWM; Department of Hematology, Umeå University Hospital, Umeå, Sweden.
Ann Hematol ; 102(6): 1395-1408, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37119314
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide de Fase Crónica / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide de Fase Crónica / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article